Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

973
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
973
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

205
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
205
What is Genetic Engineering?00:49

What is Genetic Engineering?

80.0K
Overview
80.0K
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
One-Compartment Model: IV Infusion01:09

One-Compartment Model: IV Infusion

507
Intravenous (IV) infusion is often utilized when continuous and controlled drug delivery is necessary, such as during surgery or in the treatment of chronic diseases. This method offers numerous advantages, including immediate drug action, precise control over dosage, and bypassing the first-pass metabolism.
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
507
Two-Compartment Open Model: IV Infusion01:15

Two-Compartment Open Model: IV Infusion

590
A two-compartment model is a vital tool in pharmacokinetics, providing an essential understanding of drug behavior, especially for those administered via zero-order intravenous infusion. This model outlines two compartments: the central compartment, where elimination occurs, and the peripheral compartment.
The model illustrates the decrease in plasma drug concentration from the central compartment with a specific equation. It shows that under steady-state conditions, the drug's input rate...
590

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP.

Blood advances·2026
Same author

Delayed ADAMTS13 normalisation in caplacizumab/PEX treated patients associated with anti-ADAMTS13 IgG antibody boosting.

Blood advances·2026
Same author

Refractoriness in TTP: challenges and solutions.

Blood·2026
Same author

Emerging from the shadows of congenital TTP.

Blood advances·2026
Same author

Thrombotic thrombocytopenic purpura: celebrating 25 years of ADAMTS13.

Blood·2026
Same author

Caplacizumab resistance in immune thrombotic thrombocytopenic purpura is associated with a von Willebrand factor A1 domain missense variant.

Journal of thrombosis and haemostasis : JTH·2026

Related Experiment Video

Updated: Jan 28, 2026

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
09:34

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy

Published on: May 18, 2017

8.0K

How an engineered therapy could replace the need for potentially harmful plasma infusions

Marie Scully1

  • 1a Department of Haematology , UCLH, Cardiometabolic programme- NIHR UCLH/UCL BRC , London , UK.

Expert Review of Clinical Pharmacology
|March 5, 2019
PubMed
Summary

No abstract available in PubMed .

Keywords:
ADAMTS 13TTPfresh frozen plasmarecombinant therapy

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
07:37

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Published on: November 17, 2017

13.4K

Related Experiment Videos

Last Updated: Jan 28, 2026

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
09:34

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy

Published on: May 18, 2017

8.0K
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
07:37

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Published on: November 17, 2017

13.4K